Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial.

Department of Obstetrics and Gynecology and Center for Preterm Birth Research, Washington University School of Medicine, St. Louis, Missouri, USA.
Ultrasound in Obstetrics and Gynecology (Impact Factor: 3.14). 11/2007; 30(5):697-705. DOI: 10.1002/uog.5159
Source: PubMed

ABSTRACT To investigate the efficacy of vaginal progesterone to prevent early preterm birth in women with sonographic evidence of a short cervical length in the midtrimester.
This was a planned, but modified, secondary analysis of our multinational, multicenter, randomized, placebo-controlled trial, in which women were randomized between 18 + 0 and 22 + 6 weeks of gestation to receive daily treatment with 90 mg of vaginal progesterone gel or placebo. Cervical length was measured with transvaginal ultrasound at enrollment and at 28 weeks of gestation. Treatment continued until either delivery, 37 weeks of gestation or development of preterm rupture of membranes. Maternal and neonatal outcomes were evaluated for the subset of all randomized women with cervical length < 28 mm at enrollment. The primary outcome was preterm birth at </= 32 weeks.
A cervical length < 28 mm was identified in 46 randomized women: 19 of 313 who received progesterone and 27 of 307 who received the placebo. Baseline characteristics of the two groups were similar. In women with a cervical length < 28 mm, the rate of preterm birth at </= 32 weeks was significantly lower for those receiving progesterone than it was for those receiving the placebo (0% vs. 29.6%, P = 0.014). With progesterone, there were fewer admissions into the neonatal intensive care unit (NICU; 15.8% vs. 51.9%, P = 0.016) and shorter NICU stays (1.1 vs. 16.5 days, P = 0.013). There was also a trend toward a decreased rate of neonatal respiratory distress syndrome (5.3% vs. 29.6%, P = 0.060).
Vaginal progesterone may reduce the rate of early preterm birth and improve neonatal outcome in women with a short sonographic cervical length.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent discoveries suggest that T regulatory lymphocytes (Treg) might play an important role in the pathophysiology of preterm labor. The aim of this study was to assess the relationship among the levels of maternal circulating Treg cells, uterine cervical length, and the risk of preterm labor. Sixty women with regular contractions and/or cervical incompetence at 24–32 weeks’ gestation, were recruited into a prospective study. Each patient underwent transvaginal ultrasound examination of the cervical length, and regulatory T cells were quantified in peripheral blood samples by flow cytometry. Patients with cervical incompetence were prescribed vaginal progesterone until birth. Measurements of Treg levels and cervical length correlated with the timing of labor. The risk of preterm labor happening within 48 h of testing was demonstrated to be almost 35 times higher (OR = 35.21, CI 13.3; 214, p < 0.001) in the group with simultaneously low Treg values (<0.031 × 109/L) and a shortened uterine cervix (<17.5 mm), compared with the situation where both of these values were normal. Similar results were found in predicting preterm delivery before 34 weeks, or between 34 and 37 weeks. A statistically nonsignificant trend toward increased cervical length and increased Treg count was noted in the women on progesterone treatment. We show for the first time that the combined assessment of Treg cell count and cervical length is a much better predictor of preterm delivery than either parameter used on its own. This combined approach may offer clinical application in patients who present with risk factors for preterm labor.
    Journal of Reproductive Immunology 12/2014; · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Premature remodeling of uterine cervical microstructure plays a large role in preterm birth. Invasive studies confirm that collagen, the major contributor to cervical strength, undergoes rearrangement long before changes associated with pre-delivery remodeling (shortening, softening, dilation) are grossly detectable. However, a lack of noninvasive technology sophisticated enough to interrogate the cervical microstructure makes quantitative assessment of the cervix challenging. Therefore, clinical cervical assessment is subjective. For instance, clinicians can feel a difference in softness between a nulliparous (never had babies) and multiparous (had babies) cervix. Further, they become concerned about preterm birth risk when the cervix feels “too soft” in midgestation. The inability to objectively describe these parameters impedes clinical management; in other words, currently there is no means to answer critical questions such as “how soft is too soft?”. Our preliminary results using quantitative ultrasound (QUS) techniques and shear wave sound speeds (SWS) to objectively describe cervical microstructure and softening suggest that these measurements are sensitive enough to detect differences between the nonpregnant nulliparous and multiparous cervix, and thus are promising for quantitative assessment of the cervix in pregnancy.
    Ultrasonics Symposium (IUS), 2011 IEEE International; 01/2011
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of progesterone (P4) for maintenance of pregnancy, its role in cervical ripening and uterine contractions is at least partly established and therefore, not surprisingly, the basis for the concept to use P4 as a treatment for preterm birth. Due to the complexity of the condition of preterm birth there are still questions concerning the optimal population that might benefit, timing of treatment, dosage, vehicle and route of administration. Recently vaginal P4 and intramuscular 17-alpha-hydroxyprogesterone caproate (17P) have been used to prevent preterm birth in patients with a high risk for early delivery. The aim of this study was to assess cervical changes throughout pregnancy in rats and the timing of term and preterm delivery after various progestin treatments given by different routes and vehicles in hope of identifying better treatment regimens. This paper presents results that suggest that there are better routes of treatment than the vaginal route (e.g. topical), that the vehicle used in many of the clinical studies (Replens®) is not appropriate due to a low release of the steroid and consequently low uptake of P4, and that inhibition of birth is primarily due to inhibition of uterine contractility that can be achieved by supplementation of P4 but not with 17P.
    Facts, views & vision in ObGyn. 01/2012; 4(2):110-119.

Full-text (2 Sources)

Available from
May 29, 2014